Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
May 2016

Flibanserin (Addyi): Data and Opinion
Further research is required to determine whether the modest benefits from flibanserin (Addyi) for women with acquired generalized hypoactive sexual desire disorder outweigh its risks.

Varenicline in Schizophrenia
A recent study of varenicline (Chantix) in patients with schizophrenia found that, compared with placebo, it reduced smoking without increasing psychiatric symptoms and was well tolerated but did not improve cognition.

New Treatment Approaches for Bipolar Depression
Recent studies of treatments for bipolar depression report that lamotrigine (Lamictal and others) added to quetiapine (Seroquel and others) improves depressive symptoms; folic acid may reduce the effectiveness of lamotrigine; and agomelatine is not efficacious in this population.

In Brief
Primary Care Physicians Use Management Care Processes Less for Depression than for Other Chronic Illnesses: Antipsychotic-Treated Patients with Schizophrenia Experience No Benefits from Adjunctive Oxytocin

About the Editorial Advisory Committee

Editorial Advisory Committee:
Ross J. Baldessarini, M.D.
Joseph Biederman, M.D.
Rubin Bressler, M.D.
Andrew W. Brotman, M.D.
Ned Cassem, M.D.
Harold J. DeMonaco, M.S., R.Ph.
Susan R. Donaldson, M.D.
William E. Falk, M.D.
John Greist, M.D.
James W. Jefferson, M.D.
David Katzelnick, M.D.
Samuel J. Keith, M.D.
Martin B. Keller, M.D.
John Racy, M.D.
Eric M. Reiman, M.D.
Jerrold F. Rosenbaum, M.D.
A. John Rush, M.D.
Alan F. Schatzberg, M.D.
Nina R. Schooler, Ph.D.
Michael E. Thase, M.D.
Joanne Doller Wojcik, R.N., M.S.

Editor
Alan J. Gelenberg, M.D.

Assistant Editor
Heather S. Hopkins

Managing Editor
Amy Boynton